Awareness of prolapse at one to three years was less likely after mesh repair (risk ratio (RR) 0.66, 95% confidence interval (CI) 0.54 to 0.81, 12 RCTs, n = 1614, I 2 = 3%, moderate-quality evidence). This suggests that if 19% of women are aware of prolapse after native tissue repair, between 10% and 15% will be aware of prolapse after permanent mesh repair.
Rates of repeat surgery for prolapse were lower in the mesh group (RR 0.53, 95% CI 0.31 to 0.88, 12 RCTs, n = 1675, I 2 = 0%, moderate-quality evidence). There was no evidence of a difference between the groups in rates of repeat surgery for continence (RR 1.07, 95% CI 0.62 to 1.83, 9 RCTs, n = 1284, I 2 = 21%, low-quality evidence). More women in the mesh group required repeat surgery for the combined outcome of prolapse, stress incontinence, or mesh exposure (RR 2.40, 95% CI 1.51 to 3.81, 7 RCTs, n = 867, I 2 = 0%, moderate-quality evidence). This suggests that if 5% of women require repeat surgery after native tissue repair, between 7% and 18% in the permanent mesh group will do so. Eight per cent of women in the mesh group required repeat surgery for mesh exposure.
Recurrent prolapse on examination was less likely after mesh repair (RR 0.40, 95% CI 0.30 to 0.53, 21 RCTs, n = 2494, I 2 = 73%, low-quality evidence). This suggests that if 38% of women have recurrent prolapse after native tissue repair, between 11% and 20% will do so after mesh repair.
Permanent mesh was associated with higher rates of de novo stress incontinence (RR 1.39, 95% CI 1.06 to 1.82, 12 RCTs, 1512 women, I 2 = 0%, low-quality evidence) and bladder injury (RR 3.92, 95% CI 1.62 to 9.50, 11 RCTs, n = 1514, I 2 = 0%, moderatequality evidence). There was no evidence of a difference between the groups in rates of de novo dyspareunia (RR 0.92, 95% CI 0.58 to 1.47, 11 RCTs, n = 764, I 2 = 21%, low-quality evidence). Effects on quality of life were uncertain due to the very low-quality evidence.
Absorbable mesh versus native tissue repair
There was very low-quality evidence for the effectiveness of either form of repair at two years on the rate of awareness of prolapse (RR 1.05, 95% CI 0.77 to 1.44, 1 RCT, n = 54).
There was very low-quality evidence for the effectiveness of either form of repair on the rate of repeat surgery for prolapse (RR 0.47, 95% CI 0.09 to 2.40, 1 RCT, n = 66).
Recurrent prolapse on examination was less likely in the mesh group (RR 0.71, 95% CI 0.52 to 0.96, 3 RCTs, n = 292, I 2 = 21%, lowquality evidence)
The effect of either form of repair was uncertain for urinary outcomes, dyspareunia, and quality of life.
Biological graft versus native tissue repair
There was no evidence of a difference between the groups at one to three years for the outcome awareness of prolapse (RR 0.97, 95% CI 0.65 to 1.43, 7 RCTs, n = 777, low-quality evidence).
There was no evidence of a difference between the groups for the outcome repeat surgery for prolapse (RR 1.22, 95% CI 0.61 to 2.44, 5 RCTs, n = 306, I 2 = 8%, low-quality evidence).
The effect of either approach was very uncertain for recurrent prolapse (RR 0.94, 95% CI 0.60 to 1.47, 7 RCTs, n = 587, I 2 = 59%, very low-quality evidence).
There was no evidence of a difference between the groups for dyspareunia or quality of life outcomes (very low-quality evidence).
Authors' conclusions
While transvaginal permanent mesh is associated with lower rates of awareness of prolapse, repeat surgery for prolapse, and prolapse on examination than native tissue repair, it is also associated with higher rates of repeat surgery for prolapse or stress urinary incontinence or mesh exposure (as a composite outcome), and with higher rates of bladder injury at surgery and de novo stress urinary incontinence. The risk-benefit profile means that transvaginal mesh has limited utility in primary surgery. While it is possible that in women with higher risk of recurrence the benefits may outweigh the risks, there is currently no evidence to support this position.
Limited evidence suggests that absorbable mesh may reduce rates of recurrent prolapse on examination compared to native tissue repair, but there was insufficient evidence on absorbable mesh for us to draw any conclusions for other outcomes. There was also insufficient evidence for us to draw any conclusions regarding biological grafts compared to native tissue repair.
In 2011, many transvaginal permanent meshes were voluntarily withdrawn from the market, and the newer, lightweight transvaginal permanent meshes still available have not been evaluated within a RCT. In the meantime, these newer transvaginal meshes should be utilised under the discretion of the ethics committee.
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Transvaginal mesh or grafts compared with native tissue repair for vaginal prolapse
Review question
Should transvaginal mesh or biological grafts or native tissue be utilised to repair vaginal prolapse?
Background
Pelvic organ prolapse is common, affecting as many as 50% of women who have had children. The traditional method of repairing vaginal prolapse using native tissue is associated with high rates of recurrence. It is thought that transvaginal grafts made of absorbable or permanent mesh or biological material may improve the outcomes of prolapse surgery.
Study characteristics
We evaluated 37 randomised controlled trials (4023 women) comparing transvaginal grafts versus traditional native tissue repair for repairing vaginal prolapse. The evidence is current to July 2015.
Key results
Low to moderate quality evidence suggests that there are advantages to using transvaginal permanent mesh compared to native tissue repair, including lower rates of awareness of prolapse, repeat surgery for prolapse, and recurrent prolapse on examination. The evidence suggests that if 19% of women are aware of prolapse after native tissue repair, between 10% and 15% will be aware of prolapse after permanent mesh repair. If the rate of recurrent prolapse on examination after a native tissue repair is assumed to be 38%, the risk would be between 11% and 20% after a repair with transvaginal permanent mesh. However, there are also problems associated with permanent transvaginal mesh. If we assume that 5% of women require repeat surgery for prolapse or urinary incontinence or mesh exposure (any of the three) after native tissue repair, the risk would be between 7% and 18% after permanent mesh repair. Eight per cent of women in the mesh groups required repeat surgery for mesh exposure.
Low quality evidence suggests that absorbable mesh may reduce the risk of recurrent prolapse on examination compared to native tissue repair, but there is insufficient evidence on absorbable mesh for us to draw any conclusions for other outcomes.
Low quality evidence suggests there is no difference between biological grafts and native tissue repair on rates of awareness of prolapse or reoperation for prolapse. Due to the very low quality of evidence, the impact of the interventions on prolapse on examination was uncertain.
While permanent mesh has some advantages over native tissue, there are also disadvantages in its routine use. Many transvaginal permanent meshes were withdrawn from use in 2011, and the newer, lightweight transvaginal permanent meshes still available have not been evaluated within a randomised study.
Quality of the evidence
Overall, the quality of the evidence ranged from very low to moderate. The main limitations were poor reporting of study methods, inconsistency, and imprecision.
